GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18
出版年份 2022 全文链接
标题
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-03-29
DOI
10.3389/fimmu.2022.839783
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity
- (2021) Stefan Kiesgen et al. Nature Protocols
- Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL
- (2021) Julia K. Bialek-Waldmann et al. Molecular Therapy-Methods & Clinical Development
- Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines
- (2020) Katharina Zimmermann et al. Cancers
- Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial
- (2020) Maria Castella et al. Frontiers in Immunology
- Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma
- (2020) Karin Straathof et al. Science Translational Medicine
- EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells
- (2019) Sareetha Kailayangiri et al. MOLECULAR THERAPY
- Innovation in Chemistry, Manufacturing, and Controls—A Regulatory Perspective From Industry
- (2019) Nina S. Cauchon et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
- (2019) Sandhya R. Panch et al. MOLECULAR THERAPY
- Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
- (2019) Yogindra Vedvyas et al. Scientific Reports
- Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
- (2019) Dana L. Casey et al. Frontiers in Oncology
- CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
- (2019) Lena Andersch et al. BMC CANCER
- GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
- (2019) Christian M. Seitz et al. OncoImmunology
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
- (2018) Franziska Blaeschke et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center
- (2018) Fenlu Zhu et al. CYTOTHERAPY
- A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects
- (2018) Yuki Kagoya et al. NATURE MEDICINE
- Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
- (2018) Concetta Quintarelli et al. OncoImmunology
- Teaching an old dog new tricks: next-generation CAR T cells
- (2018) Nicholas Tokarew et al. BRITISH JOURNAL OF CANCER
- Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors
- (2018) Giulia Golinelli et al. CANCER GENE THERAPY
- Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS prodigy system
- (2018) Wei Zhang et al. Drug Design Development and Therapy
- Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
- (2018) Maria Castella et al. Molecular Therapy-Methods & Clinical Development
- Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor–Based Immunotherapy and Chemotherapy
- (2017) Rüdiger Klapdor et al. HUMAN GENE THERAPY
- Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use
- (2017) Dominik Lock et al. HUMAN GENE THERAPY
- Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells
- (2017) David F. Stroncek et al. Journal of Translational Medicine
- CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
- (2017) Andras Heczey et al. MOLECULAR THERAPY
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
- (2017) Khun Visith Keu et al. Science Translational Medicine
- CAR T Cells Releasing IL-18 Convert to T-Bet high FoxO1 low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
- (2017) Markus Chmielewski et al. Cell Reports
- Development of the First World Health Organization Lentiviral Vector Standard: Toward the Production Control and Standardization of Lentivirus-Based Gene Therapy Products
- (2017) Yuan Zhao et al. Human Gene Therapy Methods
- Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors
- (2017) A. Kunert et al. OncoImmunology
- Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy
- (2016) Ulrike Mock et al. CYTOTHERAPY
- Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+T Cells for Manufacturing of Gene Therapy Medicinal Products
- (2016) Christoph Priesner et al. HUMAN GENE THERAPY
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Role of memory T cell subsets for adoptive immunotherapy
- (2016) Dirk H. Busch et al. SEMINARS IN IMMUNOLOGY
- Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G
- (2016) Sareetha Kailayangiri et al. OncoImmunology
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO
- (2014) Nikolai Siebert et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response
- (2013) Holger N. Lode et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
- (2012) D. Chinnasamy et al. CLINICAL CANCER RESEARCH
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
- (2011) M. Chmielewski et al. CANCER RESEARCH
- Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment
- (2011) Ling Zhang et al. MOLECULAR THERAPY
- Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
- (2010) F. Navid et al. CURRENT CANCER DRUG TARGETS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started